| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5846710 | Toxicology and Applied Pharmacology | 2012 | 10 Pages |
Abstract
⺠Novel approach using stem cell-derived cardiomyocytes to assess preclinical safety. ⺠HER2-targeted liposomal doxorubicin has improved safety profile vs free doxorubicin. ⺠Mechanistic data identifying differences with free doxorubicin in cardiomyocytes. ⺠Preclinical safety results support decision to proceed with Phase I clinical trials. ⺠Suggests platform may be amenable to assay preclinical toxicity of other therapies.
Related Topics
Life Sciences
Environmental Science
Health, Toxicology and Mutagenesis
Authors
Joseph G. Reynolds, Elena Geretti, Bart S. Hendriks, Helen Lee, Shannon C. Leonard, Stephan G. Klinz, Charles O. Noble, Petra B. Lücker, Peter W. Zandstra, Daryl C. Drummond, Kenneth J. Jr., Ulrik B. Nielsen, Clet Niyikiza, Samuel V. Agresta,